Syntaxin Ltd, a privately-held British company that develops medicines derived from bacterial toxins to treat chronic diseases, has appointed Eduard Holdener as a non-executive director with immediate effect.
Dr Holdener was previously chief medical officer at the pharma division of F. Hoffman La Roche.
Syntaxin’s chief executive officer, Patrick Doyle, said Dr Holdener would be a “great addition” to the company as it continues to develop its pipeline towards the clinic. The Oxford-based company was formed in 2005 as a spin-out from the UK Health Protection Agency with funding from Abingworth Management Ltd.
Source:
Syntaxin press release, 17 March 2008
Copyright 2008 Evernow Publishing Ltd